Loading...
Docoh

Autolus Therapeutics (AUTL)

Autolus Therapeutics plcis a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

AUTL stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$11.50
Low target
$11.00
High target
$12.00
Needham
Maintains
Buy
$12.00
5 Aug 22
Truist Securities
Maintains
Buy
$11.00
14 Jun 22

Calendar

10 Mar 22
13 Aug 22
31 Dec 22
Quarter (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Sep 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 310.68M 310.68M 310.68M 310.68M
Cash burn (monthly) 2.97M 5.82M (no burn) 4.41M
Cash used (since last report) 22.1M 43.27M n/a 32.82M
Cash remaining 288.57M 267.4M n/a 277.86M
Runway (months of cash) 97.1 46.0 n/a 63.0

Beta Read what these cash burn values mean

80.6% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 67 73 -8.2%
Opened positions 8 23 -65.2%
Closed positions 14 9 +55.6%
Increased positions 17 18 -5.6%
Reduced positions 26 18 +44.4%
13F shares Current Prev Q Change
Total value 1.2B 405.77M +194.9%
Total shares 73.3M 72.57M +1.0%
Total puts 0 43.6K EXIT
Total calls 44.2K 86.5K -48.9%
Total put/call ratio 0.5
Largest owners Shares Value Change
BX Blackstone 17.99M $75M 0.0%
PPF Capital Partners Fund B.V. 14.61M $94.69M 0.0%
Syncona Portfolio 7.35M $38.13M 0.0%
Nantahala Capital Management 4.35M $18.12M +6.6%
Frazier Life Sciences Management 3.75M $15.62M NEW
Citadel Advisors 3.51M $14.65M +106.9%
Arix Bioscience 3.32M $24.2M 0.0%
Frazier Life Sciences Public Fund 3.01M $18M 0.0%
Polygon Management 2.83M $11.78M +4.7%
Schroder Investment Management 1.67M $7.08M 0.0%
Largest transactions Shares Bought/sold Change
Frazier Life Sciences Management 3.75M +3.75M NEW
Frazier Management 0 -3.75M EXIT
Capital World Investors 1.06M -1.9M -64.1%
Citadel Advisors 3.51M +1.81M +106.9%
LGT Capital Partners 500K +500K NEW
DAFNA Capital Management 496.15K +496.15K NEW
Deep Track Capital 382.56K +382.56K NEW
Nantahala Capital Management 4.35M +268.82K +6.6%
SG Americas Securities 0 -250.82K EXIT
GS Goldman Sachs 375.51K +222.09K +144.8%

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Aachen, absorb, Academy, analyze, analyzing, anatomic, antibiotic, arose, ARUP, ATM, Authorisation, Autobahn, autoleucel, AVEO, Axogen, behaviour, Biomedical, BioNJ, Biopharma, bispecific, Blackstone, Bonn, Boston, Braendle, Brent, Breyanzi, BS, BV, BX, cardiac, carve, cascade, categorized, CCR, classic, classical, CMC, contemplation, costimulatory, counterparty, Curie, cut, daily, Dainippon, deactivation, deadlock, debilitate, Denver, dialled, digit, disbursement, disbursing, Disc, displace, downside, dSHP, Edgar, effector, eighteen, embedded, encumber, encumbering, faster, fell, fifteen, FKBP, floor, foot, Forge, fourteen, Franchise, FRB, freestanding, GMP, GP, guaranty, heterodimerise, hierarchy, Hodgkin, ID, IFN, ImClone, imputed, Journal, Juno, LabCorp, LAVA, Los, LP, Lugano, lymphodepletion, MBA, Melinta, Merck, metabolic, mid, Moderna, ModernaTX, Monogram, Nanostring, necessitate, neutropenia, NYSE, obecabtagene, opted, outset, paradigm, pathology, Pfizer, pharmacodynamic, PhRMA, poised, Portola, PR, proliferative, Purdue, quoted, ready, rearm, recertification, Reef, rental, repeat, reprogram, Rice, safest, Sanofi, Schering, SDPO, seasoned, speed, stably, steering, straight, stream, Strongbridge, Stroudsburg, Sumitomo, SVP, TetCAR, TG, TGF, Theravance, thinly, tumour, tuneable, Ulm, unamortized, unencrypted, unobservable, urology, VBI, Verastem, Vertex, Village, VP, wait, Whitewood
Removed: Backsolve, book, British, matching, OPM, reconciling, retroactively, scenario, Tabular, unlevered
Proxies
No filings